Table 2.
Effects of sub-chronic agmatine treatment on organ weight.
| Organ/body weight ratio | Brain | Heart | Kidney* | Liver | Spleen | Testicle |
|---|---|---|---|---|---|---|
| WT (Agm-0) | 10.96 ± 0.37 | 3.97 ± 0.19 | 6.74 ± 0.46 | 47.11 ± 1.48 | 2.75 ± 0.14 | 2.30 ± 0.11 |
| WT (Agm-300) | 11.53 ± 0.38 | 4.21 ± 0.17 | 6.58 ± 0.22 | 43.27 ± 1.52 | 2.45 ± 0.14 | 2.29 ± 0.10 |
| Tg (Agm-0) | 10.63 ± 0.23 | 3.83 ± 0.09 | 5.82 ± 0.28 | 47.20 ± 1.55 | 2.69 ± 0.20 | 2.49 ± 0.13 |
| Tg (Agm-300) | 10.62 ± 0.29 | 3.77 ± 0.1 | 5.50 ± 0.22 | 47.93 ± 1.89 | 2.58 ± 0.19 | 2.22 ± 0.08 |
Mean (± SEM) organ (mg)/body (g) ratio of the whole brain, heart, kidney, liver, spleen or testicle in wildtype (WT) and APP/PS1 (Tg) mice with oral administration of agmatine sulfate at 0 (Agm-0) or 300 (Agm-300) mg/kg (n = 13–16/group). The organs were collected on day 105 (24 hours after the final dosing).
*Indicates a significant genotype difference in kidney (see section 3.2.4. for details).